Pro Medicus shares are down 20%. Is this a buying opportunity?

One of the ASX's best companies is now materially cheaper.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Pro Medicus Ltd (ASX: PME) share price has fallen just over 20% from its recent peak on 19 February 2025, as the chart below shows. Plenty of ASX growth shares have also suffered double-digit declines in recent weeks, but it's worth asking the question of whether the ASX healthcare share is an opportunity at this lower price.

Created with Highcharts 11.4.3Pro Medicus PriceZoom1M3M6MYTD1Y5Y10YALL1 Jan 202517 Mar 2025Zoom ▾6 Jan13 Jan20 Jan27 Jan3 Feb10 Feb17 Feb24 Feb3 Mar10 Mar17 Mar13 Jan13 Jan27 Jan27 Jan10 Feb10 Feb24 Feb24 Feb10 Mar10 Marwww.fool.com.au

Before diving into analysing the business, I'd say Pro Medicus is arguably the best business on the ASX. Its high price-earnings (P/E) ratio has been very high for a long time – it still is. It's currently valued at 296x FY24's earnings.

I recently decided to make a relatively small investment into Pro Medicus shares after the heavy decline.

It's a possibility the Pro Medicus share price could fall further from here, but I decided to take the plunge and buy a small number of shares – despite the triple-digit P/E ratio – for a few key reasons beyond the valuation decline.

Stronger profit margins

I've always been impressed by the profit margins the company has achieved, with both its gross profit margin and the operating profit (EBIT) margin.

The business positively surprised me when it reported its FY25 half-year result by stating how strong its EBIT margin had become. I think this bodes well for further EBIT margin growth in the coming years as it adds revenue to its financials from newly won contracts.

The company revealed the EBIT margin grew from 66% in HY24 to 71.9% in HY25. Considering the EBIT margin was already extremely high, this level of improvement was exceptional.

Pro Medicus has won a number of new contracts in recent times and I think it could win further contracts in the US and beyond in the coming years.

Additional growth avenues

The company has achieved an excellent (and growing) position in the radiology software space in North America. I think the company has a very promising growth outlook in this area in the coming years.

Pro Medicus is doing work on both AI and other 'ologies', which I think could help diversify and grow the company's earnings further. When asked about these two areas, the Pro Medicus CEO Sam Hupert said in an interview (which was released to the ASX):

We have continued to make good progress on both fronts. We showed some of our new 'work in progress' AI projects at RSNA in December and received very positive feedback. We have also continued to make progress with our cardiology offering and have signed our first contract for our new cardiac echo-package, which we are looking to implement in the April timeframe. Whilst the contract is with one of our smaller customers, we see this as a material first step.

Potential profit growth

The valuation of ASX shares is usually influenced by how much profit investors think the business will make in the coming years. Given the high Pro Medicus share price, the market is clearly expecting a lot from the company.

It's true that the business is trading at a very high level for how much profit it made in FY24. But, profit could keep rising at a fast pace over the rest of the decade, making today's valuation seem less expensive.

For example, in the first half of FY25, the company grew its net profit after tax (NPAT) by 42.7%.

The business has signed a number of contracts that should help its profit rise in the coming years. In November 2024, it signed a 10-year contract with Trinity Health (one of the largest not-for-profit healthcare systems in the US) for A$330 million. It has signed a number of smaller contracts since then too.

If the EBIT margin rises even further, then this additional revenue could become increasingly valuable for Pro Medicus shares.

Motley Fool contributor Tristan Harrison has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »